Bone Biologics Corporation
BBLG
$2.48
-$0.09-3.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.19% | -6.54% | -36.82% | 3.02% | -38.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.61% | 14.94% | 34.04% | -54.30% | -73.36% |
| Operating Income | 7.61% | -14.94% | -34.04% | 54.30% | 73.36% |
| Income Before Tax | 5.51% | -17.45% | 1.82% | 50.98% | 55.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.51% | -17.45% | 1.82% | 50.98% | 55.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.51% | -17.45% | 1.82% | 50.98% | 55.70% |
| EBIT | 7.61% | -14.94% | -34.04% | 54.30% | 73.36% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 67.00% | 75.61% | 81.83% | 51.65% | 87.14% |
| Normalized Basic EPS | 67.00% | 75.61% | 75.19% | 89.05% | 87.14% |
| EPS Diluted | 67.00% | 75.61% | 81.83% | 51.65% | 87.14% |
| Normalized Diluted EPS | 67.00% | 75.61% | 75.19% | 89.05% | 87.14% |
| Average Basic Shares Outstanding | 186.34% | 381.40% | 440.26% | 347.47% | 244.17% |
| Average Diluted Shares Outstanding | 186.34% | 381.40% | 440.26% | 347.47% | 244.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |